Zonisamide add-on therapy for focal epilepsy

Area of Science:

• Neurology
• Pharmacology
• Clinical Trials

Background:

• Refractory epilepsy affects up to 30% of epilepsy patients, particularly those with focal seizures.
• Zonisamide is an antiepileptic drug used in treatment regimens.
• This review is an update of a previous Cochrane review from 2013.

Purpose of the Study:

• To evaluate the efficacy and tolerability of zonisamide as an add-on treatment for focal epilepsy.
• To assess zonisamide's effectiveness in patients whose seizures are not controlled by existing antiepileptic drugs.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs).
• Searched multiple databases including Cochrane Epilepsy Group Register, MEDLINE, and ClinicalTrials.gov.
• Assessed risk of bias using the Cochrane 'Risk of bias' tool and evidence quality using the GRADE approach.

Main Results:

• Zonisamide (300-500 mg/day) significantly reduced seizure frequency by at least 50% compared to placebo (RR 1.90, moderate-quality evidence).
• The number needed to treat for an additional beneficial outcome was six.
• Adverse effects associated with zonisamide included ataxia, somnolence, agitation, and anorexia.

Conclusions:

• Zonisamide demonstrates moderate-quality evidence of efficacy in reducing seizure frequency for refractory focal epilepsy.
• Longer-term efficacy and optimal dosing require further investigation.
• Results are not generalizable to monotherapy or other epilepsy types.